Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Gastroenterology

Journal Scan / Research · January 21, 2024

Ebastine vs Placebo for the Treatment of Patients With Non-Constipated IBS



Additional Info

Disclosure statements are available on the authors' profiles:

Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial
Gut 2024 Jan 08;[EPub Ahead of Print], L Decraecker, D De Looze, DP Hirsch, H De Schepper, J Arts, P Caenepeel, AJ Bredenoord, J Kolkman, K Bellens, K Van Beek, F Pia, W Peetermans, T Vanuytsel, A Denadai-Souza, A Belmans, G Boeckxstaens

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading